Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regenerative Meds: Indian Drug Makers Inject New Life Through Investments In Stem Cells

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Leading Indian companies are gearing up for emerging frontiers in medicine research, and among all the segments, regenerative therapies seem to be driving more and more initial investments from mainstream pharma companies

You may also be interested in...



India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D

MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes

India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D

MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes

Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For "Niche Busters" And Stem Cells

MUMBAI - Research-related investments funnelled into India by U.S.-based pharmaceutical companies swelled by 10 times between 2002 and 2009 to reach $121 million, a number that will continue to grow in the years to come, according to an upcoming study by the Boston Consulting Group. The report, which was commissioned by the USA-India Chamber of Commerce (USAIC), will be released June 23 during the annual USA-India BioPharma & Healthcare Summit in Boston

Related Content

UsernamePublicRestriction

Register

SC075180

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel